West Pharmaceutical Services, Inc. - Q2 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2026. West Pharmaceutical Services, Inc. is a global manufacturer of containment and delivery systems for injectable drugs. The company operates two reportable segments: Proprietary Products (packaging, containment, and drug delivery) and West Vantage (formerly Contract-Manufactured Products, renamed in Q1 2026), which focuses on complex device design and assembly.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Net Sales | $872.3 million | $766.5 million | $1,717.2 million | $1,464.5 million |
| Gross Profit | $329.2 million | $273.9 million | $625.6 million | $505.8 million |
| Gross Margin | 37.7% | 35.7% | 36.4% | 34.5% |
| Operating Profit | $179.1 million | $153.7 million | $356.2 million | $260.7 million |
| Net Income | $154.0 million | $131.8 million | $292.8 million | $221.6 million |
| Diluted EPS | $2.15 | $1.82 | $4.07 | $3.05 |
| Cash & Equivalents | $435.8 million (as of June 30, 2026) | |||
| Long-Term Debt | $202.9 million (as of June 30, 2026) | |||
| Operating Cash Flow (YTD) | $213.9 million |
Material Changes vs. Prior Period
- Revenue Growth: Consolidated net sales increased 13.8% in Q2 and 17.3% YTD compared to 2025. Organic growth was 12.7% in Q2 and 13.9% YTD, driven by volume/mix and price increases.
- Segment Performance:
- Proprietary Products: Sales grew 16.6% in Q2, driven by strong demand for High-Value Product (HVP) components (Biologics and GLP-1) and delivery devices.
- West Vantage: Sales grew 2.0% in Q2. Growth was partially offset by approximately $7 million in lost revenue due to production downtime from a May 2026 cybersecurity incident.
- Profitability: Operating profit increased 16.5% in Q2. Adjusted operating profit margin expanded to 22.6% in Q2 (from 20.3% in 2025) and 22.0% YTD (from 19.1% in 2025).
- Share Repurchases: The company repurchased 1.76 million shares for $454.3 million YTD 2026, a significant increase from $134.0 million in the same period in 2025.
- Asset Sale: On July 1, 2026 (post-period), the company completed the sale of the SmartDose 3.5mL On-Body Delivery System to AbbVie for approximately $136 million, expecting a pre-tax gain of $55–$60 million in Q3 2026.
Guidance, Outlook, Risks, and Unusual Items
- Cybersecurity Incident: A material cyberattack in May 2026 resulted in data exfiltration and system encryption, causing temporary global operational disruption and estimated $7 million in lost revenue for West Vantage. Operations have fully recovered.
- Unallocated Items: Q2 2026 results included $18.3 million in unallocated items (non-GAAP adjustments), primarily related to M&A activities ($6.4 million), cost-method investment impairments ($3.5 million), and nonrecurring professional fees ($6.9 million) associated with the cyber incident and legal matters.
- Tax Rate: The effective tax rate for the six months ended June 30, 2026, was 21.3%, increased by a one-time $12.0 million tax cost from an internal legal entity restructuring in Q1.
- Legal Proceedings: A securities class action lawsuit filed in May 2025 regarding public statements and officer stock transactions is ongoing; the company intends to vigorously defend the claims.
- Outlook: Management does not expect current trade policy changes or Middle East conflicts to have a material impact on 2026 results. The company expects to recognize the gain on the SmartDose sale in Q3 2026.
Investor Verification Checklist
- Verify the final working capital adjustment and total proceeds from the SmartDose 3.5mL sale to AbbVie upon Q3 2026 reporting.
- Monitor the long-term financial impact of the May 2026 cybersecurity incident, including potential insurance recoveries and future remediation costs.
- Review the status of the securities class action lawsuit and any potential settlement discussions.
- Assess the sustainability of the 12.7% organic sales growth, particularly the reliance on GLP-1 and Biologics demand.
- Confirm the company's ability to maintain debt covenant compliance given the significant cash outflow from share repurchases ($454.3 million YTD).